BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25367255)

  • 1. AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.
    Juan G; Bush TL; Ma C; Manoukian R; Chung G; Hawkins JM; Zoog S; Kendall R; Radinsky R; Loberg R; Friberg G; Payton M
    J Transl Med; 2014 Nov; 12():307. PubMed ID: 25367255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
    Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
    Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
    Bush TL; Payton M; Heller S; Chung G; Hanestad K; Rottman JB; Loberg R; Friberg G; Kendall RL; Saffran D; Radinsky R
    Mol Cancer Ther; 2013 Nov; 12(11):2356-66. PubMed ID: 23990115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.
    Payton M; Cheung HK; Ninniri MSS; Marinaccio C; Wayne WC; Hanestad K; Crispino JD; Juan G; Coxon A
    Mol Cancer Ther; 2018 Dec; 17(12):2575-2585. PubMed ID: 30266802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.
    Paller CJ; Wissing MD; Mendonca J; Sharma A; Kim E; Kim HS; Kortenhorst MS; Gerber S; Rosen M; Shaikh F; Zahurak ML; Rudek MA; Hammers H; Rudin CM; Carducci MA; Kachhap SK
    Cancer Med; 2014 Oct; 3(5):1322-35. PubMed ID: 24989836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
    Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
    In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.
    Carducci M; Shaheen M; Markman B; Hurvitz S; Mahadevan D; Kotasek D; Goodman OB; Rasmussen E; Chow V; Juan G; Friberg GR; Gamelin E; Vogl FD; Desai J
    Invest New Drugs; 2018 Dec; 36(6):1060-1071. PubMed ID: 29980894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.
    Romanelli A; Clark A; Assayag F; Chateau-Joubert S; Poupon MF; Servely JL; Fontaine JJ; Liu X; Spooner E; Goodstal S; de Cremoux P; Bièche I; Decaudin D; Marangoni E
    Mol Cancer Ther; 2012 Dec; 11(12):2693-703. PubMed ID: 23012245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line.
    Borges KS; Andrade AF; Silveira VS; Marco Antonio DS; Vasconcelos EJR; Antonini SRR; Tone LG; Scrideli CA
    Anticancer Drugs; 2017 Jul; 28(6):634-644. PubMed ID: 28410270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
    Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D
    Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
    Farrell P; Shi L; Matuszkiewicz J; Balakrishna D; Hoshino T; Zhang L; Elliott S; Fabrey R; Lee B; Halkowycz P; Sang B; Ishino S; Nomura T; Teratani M; Ohta Y; Grimshaw C; Paraselli B; Satou T; de Jong R
    Mol Cancer Ther; 2013 Apr; 12(4):460-70. PubMed ID: 23358665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
    Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
    J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
    Geron L; Borges KS; Andrade AF; Suazo VK; Scrideli CA; Tone LG
    Neurol Res; 2015 Aug; 37(8):703-11. PubMed ID: 26000978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.
    Geuns-Meyer S; Cee VJ; Deak HL; Du B; Hodous BL; Nguyen HN; Olivieri PR; Schenkel LB; Vaida KR; Andrews P; Bak A; Be X; Beltran PJ; Bush TL; Chaves MK; Chung G; Dai Y; Eden P; Hanestad K; Huang L; Lin MH; Tang J; Ziegler B; Radinsky R; Kendall R; Patel VF; Payton M
    J Med Chem; 2015 Jul; 58(13):5189-207. PubMed ID: 25970324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
    Kalous O; Conklin D; Desai AJ; Dering J; Goldstein J; Ginther C; Anderson L; Lu M; Kolarova T; Eckardt MA; Langerød A; Børresen-Dale AL; Slamon DJ; Finn RS
    Breast Cancer Res Treat; 2013 Oct; 141(3):397-408. PubMed ID: 24091768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
    Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
    J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.
    Jani JP; Arcari J; Bernardo V; Bhattacharya SK; Briere D; Cohen BD; Coleman K; Christensen JG; Emerson EO; Jakowski A; Hook K; Los G; Moyer JD; Pruimboom-Brees I; Pustilnik L; Rossi AM; Steyn SJ; Su C; Tsaparikos K; Wishka D; Yoon K; Jakubczak JL
    Mol Cancer Ther; 2010 Apr; 9(4):883-94. PubMed ID: 20354118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
    Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
    Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors.
    Karra S; Xiao Y; Chen X; Liu-Bujalski L; Huck B; Sutton A; Goutopoulos A; Askew B; Josephson K; Jiang X; Shutes A; Shankar V; Noonan T; Garcia-Berrios G; Dong R; Dhanabal M; Tian H; Wang Z; Clark A; Goodstal S
    Bioorg Med Chem Lett; 2013 May; 23(10):3081-7. PubMed ID: 23570792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.
    Carpinelli P; Ceruti R; Giorgini ML; Cappella P; Gianellini L; Croci V; Degrassi A; Texido G; Rocchetti M; Vianello P; Rusconi L; Storici P; Zugnoni P; Arrigoni C; Soncini C; Alli C; Patton V; Marsiglio A; Ballinari D; Pesenti E; Fancelli D; Moll J
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3158-68. PubMed ID: 18089710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.